Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related macular degene...
Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EG...
Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomod...
-JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III cli...
Artelo Biosciences, Inc. a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people liv...
In a significant move to accelerate the global fight against blood cancers and hard-totreat solid tumours, renowned end- to-end biologics CDMO Mabion hav...
Clinical-stage biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that recruitment activities are progressing rapidly and on sche...
Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Ph...
EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial. ...
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with...
Ipsen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion...
The BIO International Convention 2025 concluded in Boston with an exceptional display of biopharmaceutical innovation, regulatory dialogue, investment di...
Transformative Science and Global Health Solutions The convention floor buzzed with activity as Azitra, Inc. confirmed its pivotal presentation on novel...
Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispeci...
© 2025 Biopharma Boardroom. All Rights Reserved.
